Search results for " drug delivery" in Articles / App Notes

Article A Look Ahead at BioPharma Manufacturing and Regulation
The FDA talks about the changing scope of regulatory science. Regulatory science underpins innovation and practices in drug manufacturing. The most common definition of r…

Article A Diverse Landscape of Patent Issues Seen in the US, UK, and the EU
A Diverse Landscape of Patent Issues Seen in the US, UK, and the EU Legal experts in biopharmaceutical patent law shed some light on trends and recent news. By Agnes Shanley …

Article Biopharma Seeks Balance
Biopharma Seeks Balance Biopharma companies can balance competing demands from patients, investors, and regulators by keeping a focus on science. By Rita C. Peters …

Article Framing Biopharma Success in 2016
Corporate restructurings, regulatory initiatives, and biosimilars will shape biopharma development in 2016. By Rita C. Peters The US biopharmaceutical industry turned a new page in 2015 when…

Article mAbs to Watch in 2016
By Randi Hernandez Of the 45 new molecular entities and new therapeutic biological products approved by FDA in 2015, nine products were monoclonal antibodies (mAbs). And there may be many more o…

Article Biopharma Advances Demand Specialized Expertise
Jun 15, 2015 By BioPharm International Editors BioPharm International eBooks Volume 28, Issue 13 Contract service providers share insights on biopharma market developments and the impl…

Article Pandemic Alters Policies and Practices for Drug Development and Regulation
By Jill Wechsler The need for medicines to combat COVID-19 has impacted the way regulatory agencies carry out their operations. Drug development and regulati…

Article Transformative Medicines Challenge FDA and Manufacturers
FDA officials emphasize the importance of achieving consistency throughout the agency in making timely decisions on combination product oversight to support the development and approval of innovative …

Article ADC Development Robust Despite Lackluster Performance
ADC Development Robust Despite Lackluster Performance Despite the disappointing therapeutic performance of ADCs thus far, the pipeline still boasts promising prospects. By Feliza…

Article Witnessing Major Growth in Next-Generation Antibodies
Including next-gen antibodies in pharma pipelines is considered essential for future success. By Cynthia A. Challener Next-generation antibodies are designed to be more specific and are ofte…

Show All Results

Next Page